Skip to content

Tivozanib hydrochloride monohydrate

Zanaflex, Fotivda (tivozanib hydrochloride) is a small molecule pharmaceutical. Tivozanib hydrochloride was first approved as Zanaflex on 2017-08-24. It has been approved in Europe to treat renal cell carcinoma.
Trade Name Fotivda
Common Name Tivozanib hydrochloride monohydrate
Indication renal cell carcinoma
Drug Class Angiogenesis inhibitors
Tivozanib hydrochloride monohydrate
Get full access now